medigraphic.com
ISSN 1561-2937 (Print)

2020, Number 3

<< Back Next >>

Rev Cubana Cardiol Cir Cardiovasc 2020; 26 (3)

Cardiac arrhythmias in patients with COVID-19. Scenarios and treatment

Gutiérrez LA, Cruz CM, Mengana BA, Castañeda CO, Martínez LF, Falcón RR

Language: Spanish
References: 57
Page: 1-12
PDF size: 707.81 Kb.


ABSTRACT

COVID-19 is a global health emergency. Cardiac arrhythmias are associated with cardiac damage and high mortality. There are at least three scenarios where they can occur: triggered by infection; in patients with a history of them; secondary to proarrhythmia due to antiviral drugs. This article aims to describe these scenarios and the treatment of cardiac arrhythmias in each one of them.


REFERENCES

  1. Johns Hopkins University CSSE. Wuhan coronavirus (2019-nCoV) global cases (https://gisanddata.maps.arcgis.com).

  2. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019;17(3):181-192. https://doi.org/10.1038/s41579-018-0118-9.

  3. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579(7798):270-273. https://doi.org/10.1038/s41586-020-2012-7.

  4. van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med 2020. https://doi.org/10.1056/NEJMc2004973.

  5. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-an update on the status. Mil Med Res 2020;7(1):11. https://doi.org/10.1186/s40779-020-00240-0.

  6. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020. https://doi.org/10.1001/jama.2020.1585.

  7. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol 2020. https://doi.org/10.1001/jamacardio.2020.1286.

  8. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients WithCOVID-19 in Wuhan, China. JAMA Cardiology 2020. https://doi.org/10.1001/jamacardio.2020.0950.

  9. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020. https://doi.org/10.1016/S2213-2600(20)30116-8.

  10. Kusumoto FM, Bailey KR, Chaouki AS, Deshmukh AJ, Gautam S, Kim RJ, et al. Systematic review for the 2017 AHA / ACC / HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm. 2018;15(10):e253-74.

  11. MINSAP. Protocolo vs COVID-19. MINSAP Cuba 4 de abril de 2020. 2020;1-103.

  12. Viskin S, Havakuk O, Schwaber MJ. Pro-Arrhythmic Effects of Noncardiac Medications. J Am Coll Cardiol. 2015;66(20):2185– 8.

  13. Cheng YJ, Nie XY, Chen XM. The role of macrolide antibiotics in increasing cardiovascular risk. J Am Coll Cardiol 2015;66:2173–84.

  14. Bardai A, Amin AS, Blom MT. Sudden cardiac arrest associated with use of a non-cardiac drug that reduces cardiac excitability: evidence from bench, bedside, and community. Eur Heart J. 2013;34:1506–16.

  15. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020. https://doi.org/10.1001/jamacardio.2020.1017.

  16. Santos RAS, Sampaio WO, Alzamora AC, Motta-Santos D, Alenina N, Bader M, Campagnole-Santos MJ. The ACE2/Angiotensin-(1-7)/MAS Axis of the ReninAngiotensin System: Focus on Angiotensin-(1-7). Physiol Rev 2018;98(1):505-553. https://doi.org/10.1152/physrev.00023.2016.

  17. Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovascular Research 2020. https://doi.org/10.1093/cvr/cvaa078.

  18. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020. https://doi.org/10.1016/j.cell.2020.02.052.

  19. Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med 2020. https://doi.org/10.1007/s11684- 020-0754-0.

  20. Wu Y. Compensation of ACE2 Function for Possible Clinical Management of 2019-nCoVInduced Acute Lung Injury. Virol Sin 2020. https://doi.org/10.1007/s12250-020- 00205-6.

  21. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory Medicine 2020. https://doi.org/10.1016/S2213-2600(20)30076-X.

  22. Chen C, Zhou Y, Wang DW. SARS-CoV-2: a potential novel etiology of fulminant myocarditis. Herz 2020. https://doi.org/10.1007/s00059-020-04909-z.

  23. Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. Prog Cardiovasc Dis 2020. https://doi.org/10.1016/j.pcad.2020.03.001.

  24. Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020. https://doi.org/10.1001/jamacardio.2020.1096.

  25. Han Y, Zeng H, Jiang H, Yang Y, Yuan Z, Cheng X, et al. CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases during the COVID-19 Epidemic. Circulation 2020. https://doi.org/10.1161/CIRCULATIONAHA.120.047011.

  26. Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg F, et al. COVID-19 and the cardiovascular system - implications for risk assessment, diagnosis and treatment options. Cardiovasc Res. 2020;In press. https://doi.org/10.1093/cvr/cvaa106.

  27. Ambrus DB, Benjamin EJ, Bajwa EK, Hibbert KA, Walkey AJ. Risk factors and outcomes associated with new-onset atrial fibrillation during acute respiratory distress syndrome. J Crit Care 2015;30(5):994-7. https://doi.org/10.1016/j.jcrc.2015.06.003.

  28. Klein Klouwenberg PM, Frencken JF, Kuipers S, Ong DS, Peelen LM, van Vught LA, et al. Incidence, Predictors, and Outcomes of New-Onset Atrial Fibrillation in Critically Ill Patients with Sepsis. A Cohort Study. Am J Respir Crit Care Med 2017;195(2):205- 211. https://doi.org/10.11/rccm.201603-0618OC.

  29. Walkey AJ, Hammill BG, Curtis LH, Benjamin EJ. Long-term outcomes following development of new-onset atrial fibrillation during sepsis. Chest 2014;146(5):1187- 1195. https://doi.org/10.1378/chest.14-0003.

  30. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA 2020. https://doi.org/10.1001/jama.2020.4683.

  31. Boriani G, Fauchier L, Aguinaga L, Beattie JM, Blomstrom Lundqvist C, Cohen A, et al. Group ESCSD. European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society o Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS). Europace 2019;21(1):7-8. https://doi.org/10.1093/europace/euy110.

  32. Guías ESC 2016 sobre diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración con la EACTS. Rev Esp Cardiol. 2016;70(1):43.1-84.

  33. Brugada J, Katritsis DG, Arbelo E, Arribas F, Bax JJ, Blomstrom-Lundqvist C, et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J 2020;41(5):655- 720. https://doi.org/10.1093/eurheartj/ehz467.

  34. Issa ZF, Miller JM, Zipes DP. Clinical Arrhythmology and Electrophysiology. A Companion to Braunwald’s Heart Disease. Second Edition. Boston: Elsevier; 2015.

  35. Gillis AM. Proarrhythmia Syndromes. Second Edi. Electrophysiological Disorders of the Heart. Elsevier Inc.; 2016. 771-e105 p.

  36. Viskin S. The long QT syndromes and torsade de pointes. Lancet 1999;354:1625–33.

  37. Maruyama M. Management of electrical storm : The mechanism matters. J Arrhythmia. 2014;30:242–9.

  38. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research 2020;30(3):269-271. https://doi.org/10.1038/s41422-020-0282-0.

  39. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases 2020. https://doi.org/10.1093/cid/ciaa237.

  40. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020:105949. https://doi.org/10.1016j.ijantimicag.2020.105949.

  41. Poluzzi E, Raschi E, Motola D, Moretti U, De Ponti F. Antimicrobials and the Risk of Torsades de Pointes. Drug Safety 2010;33(4):303-314. https://doi.org/10.2165/11531850-000000000-00000.

  42. Sagara I, Oduro AR, Mulenga M, Dieng Y, Ogutu B, Tiono AB, et al. Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in two multi-country randomised clinical trials in African adults. Malaria Journal 2014;13(1):458. https://doi.org/10.1186/1475-2875-13-458.

  43. Chan JF W, Yao Y, Yeung ML, Deng W, Bao L, Jia L, et al. Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset. The Journal of Infectious Diseases 2015;212(12):1904-1913. https://doi.org/10.1093/infdis/jiv392.

  44. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. New Eng J of Med 2020. https://doi.org/10.1056/NEJMoa2001282.

  45. Morady F, Zipes YDP. Fibrilación auricular: manifestaciones clínicas, mecanismos y tratamiento global [Internet]. Eleventh E. Braunwald. Tratado de cardiología 2vols 11ed. Elsevier Espa8#241;a, S.L.U.; 2020. 730-752 p. Available from: http://dx.doi.org/10.1016/B978-84-9113-398-8/00038-1.

  46. Society E. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. 2020;1–119.

  47. University of Liverpool. COVID-19 Drug Interactions - Prescribing resources. (April 12, 2020; date last accessed). https://www.covid19-druginteractions.org/.

  48. Lapointe NMA, Sun J, Kaplan S. In-hospital management of patients with atrial flutter. Am Heart J [Internet]. 2004;159(3):370–6. Available from: http://dx.doi.org/10.1016/j.ahj.2009.12.013.

  49. Guías ESC 2016 sobre diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración con la EACTS. Rev Esp Cardiol. 2016;70(1):43.1-84.

  50. Kusumoto FM, Bailey KR, Chaouki AS, Deshmukh AJ, Gautam S, Kim RJ, et al. Systematic review for the 2017 AHA / ACC / HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death Clinical Practice Guidelines and the Heart Rhythm Society. Hear Rhythm [Internet]. 2018;15(10):e253–74. Available from: http://dx.doi.org/10.1016/j.hrthm.2017.10.037.

  51. Society E. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. 2020;1–119.

  52. Madjid M, Connolly AT, Nabutovsky Y, Safavi-Naeini P, Razavi M, Miller CC. Effect of High Influenza Activity on Risk of Ventricular Arrhythmias Requiring Therapy in Patients With Implantable Cardiac Defibrillators and Cardiac Resynchronization Therapy Defibrillators. Am J Cardiol 2019;124(1):44- 50. https://doi.org/10.1016/j.amjcard.2019.04.011.

  53. Wu CI, Postema PG, Arbelo E, Behr ER, Bezzina CR, Napolitano C, et al. SARS-CoV-2, COVID-19 and inherited arrhythmia syndromes. Heart Rhythm. https://doi.org/10.1016/j.hrthm.2020.03.024.

  54. Chang D, Saleh M, Garcia-Bengo Y, Choi E, Epstein L, Willner J. COVID-19 Infection Unmasking Brugada Syndrome. Heart Rhythm Case Reports. https://doi.org/10.1016/j.hrcr.2020.03.012.

  55. Drew BJ, Ackerman MJ, Funk M. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010;55:934–47.

  56. Zeltser D, Justo D, Halkin A. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine 2003;82:282–90.

  57. Mitra RL, Fhrs F, Greenstein SA, Epstein LM. An algorithm for managing QT prolongation in Coronavirus Disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: Possible benefits of intravenous lidocaine. Hear Case Reports [Internet]. 2020;2019. Available from: https://doi.org/10.1016/j.hrcr.2020.03.016.




2020     |     www.medigraphic.com